Live tape
Top 8, mentions 7d7,498META2,261 mentions▲ +0.06GOOGL1,504 mentions▲ +0.02NVDA795 mentions▲ +0.09MUSE665 mentions▲ +0.07MSFT602 mentions▲ +0.05SPY567 mentions▲ +0.05QQQ555 mentions▲ +0.08TSLA549 mentions▲ +0.06

Equity · Healthcare

ADMA

ADMA Biologics, Inc. · NasdaqGM

$9.39 −1.31% vs prior close Finazon · prior-day close, indicative (IEX-derived, not the official close) · Sep 25, 2026
Price · Chart
Our own end-of-day closes 62 sessions
$11 $8 30 Jun 25 Sep

The line runs $8.37 on 30 June through $9.39 on 25 September, on a scale from $8 to $11. Days the market did not trade hold the previous close, flat.

Track this symbol on TradingView

The chart above plots the price of ADMA over the range selected — one day to the full history — drawn by TradingView from their own data. Our own licensed end-of-day series holds 62 sessions over that window: $8.37 on 30 June 2026 through $9.39 on 25 September 2026.

Market cap $2.1B
P/E (TTM) 13.4
52-week range $7.59 – $20
Avg volume 187.4K

Finazon · prior-day close, indicative (IEX-derived, not the official close) · valuation computed from SEC EDGAR filings · as of Sep 25, 2026

ADMA insider trades

SEC Form 4 · last 90 days · newest Form 4 filing 24 Jul 2026
Open-market buys 0
Open-market sells 0
Non-trade filings 2

Compensation mechanics Share grants, option exercises, tax withholding and transfers. They reach the same Form 4 as a trade, but they are not the insider buying or selling on the open market, so no purchase or sale value applies to them.

Date Insider Type Shares Value
24 Jul 2026 Kestenberg-Messina Kaitlin M. COO and SVP, Compliance Tax withheld 3,177 $27K
16 Jul 2026 Kohler Terry CFO and Treasurer Award 85,130

ADMA reported financials

SEC EDGAR XBRL

ADMA reported revenue of $510.2M for the fiscal year ended 31 Dec 2025. Net income over the same period was $146.9M.

Figure Reported Period
Revenue $510.2M 31 Dec 2025 fiscal year
Net income $146.9M 31 Dec 2025 fiscal year
Diluted EPS $0.60 31 Dec 2025 fiscal year
Total assets $684.2M 30 Jun 2026 at period end
Total equity $408.2M 30 Jun 2026 at period end

Source: SEC EDGAR XBRL company facts · latest period ended 30 Jun 2026

ADMA earnings

SEC EDGAR
Date Period EPS Revenue
30 Jun 2026 Q2 2026 $0.16 —
31 Mar 2026 Q1 2026 $0.19 —
31 Dec 2025 FY 2025 $0.60 —
30 Sep 2025 Q3 2025 $0.15 —
30 Jun 2025 Q2 2025 $0.14 —
31 Mar 2025 Q1 2025 $0.11 —
31 Dec 2024 FY 2024 $0.81 —
30 Sep 2024 Q3 2024 $0.15 —

Next report no date announced in SEC filings yet

Reported figures & scheduled dates · SEC EDGAR filings

ADMA institutional holders

SEC Form 13F

12 of the 45 institutional funds we track reported a ADMA position for the quarter ended 30 Jun 2026 — a combined $147.1M; the latest of those filings landed 02 Sep 2026.

Fund Action Shares Value
D. E. Shaw & Co. Added +840.5% shares 5,274,597 $44.1M
Duquesne Family Office Added +80.1% shares 2,784,110 $23.3M
Two Sigma Investments Held (±25%) −3.5% shares 2,019,887 $16.9M
Fundsmith Held (±25%) 1,649,493 $13.8M
AQR Capital Management Added +196.4% shares 1,525,581 $12.8M
Citadel Advisors Trimmed −76.4% shares 1,370,071 $11.5M
Millennium Management Trimmed −66.4% shares 1,154,228 $9.7M
Renaissance Technologies Trimmed −48.3% shares 652,530 $5.5M
Point72 Asset Management Trimmed −87.4% shares 413,935 $3.5M
Bridgewater Associates Held (±25%) −15.0% shares 401,059 $3.4M

Showing the 10 largest of 12 reported positions. The figures above count all of them.

Source: SEC EDGAR 13F filings

ADMA fails-to-deliver

SEC CNS data

On 19 Aug 2026, 212 shares of ADMA failed to deliver (about $2K).

Settlement date Shares failed Notional % of shares out
19 Aug 2026 212 $2K <0.001%

Source: SEC fails-to-deliver (CNS) data